RT Journal Article SR Electronic T1 Carboplatin and Weekly Paclitaxel in Non-small Cell Lung Cancer Patients Unfit for or Pretreated with Chemotherapy JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 2555 OP 2559 VO 25 IS 3C A1 GIANMAURO NUMICO A1 IDA COLANTONIO A1 MILENA GASCO A1 GIANFILIPPO BERTELLI A1 ORNELLA GARRONE A1 MARCELLA OCCELLI A1 ELENA FEA A1 GIANNA DI COSTANZO A1 CRISTINA GRANETTO A1 ABDELAMID HEOUAINE A1 ELVIO RUSSI A1 MARCO MERLANO YR 2005 UL http://ar.iiarjournals.org/content/25/3C/2555.abstract AB Background: Carboplatin-Paclitaxel is one of the most active regimens in non-small cell lung cancer (NSCLC). We assessed the administration of weekly Paclitaxel as second-line chemotherapy, or as first-line chemotherapy in unfit patients. Patients and Methods: Forty-eight patients received Carboplatin at the dose of 6 x area under the concentration-time curve (AUC) on day 1 and Paclitaxel 100 mg/m2 on days 1, 8, 15 every 28. Thirty-two had received a prior platinum-based treatment, while 16 were chemotherapy-naive, unfit patients. Results: Grade 3-4 neutropenia occurred in 16 patients (33%); grade 3-4 thrombocytopenia in 7 (15%); grade 1-3 peripheral sensory neuropathy in 35 (73%). Nineteen patients (39.6%; 95% C.I.: 25.8% - 53.4%) achieved an objective response without any difference between the first-line and second-line group. One-year survival was 39.5% (95% CI: 25.4% - 53.6%). Conclusion: The impressive activity of this regimen makes it suitable for further investigation in the second-line setting. Toxicity seen in the unfit population mandates some modification of the regimen.